NCT07637851 Ubamatamab Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07637851 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 7 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07637851 is a hot trial to watch
Ovarian Cancer is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07637851 is notable because it evaluates Ubamatamab in a Phase 1/2 design sponsored by Arcagy-Gineco. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07637851 |
| Official title | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (RegeNovar) |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | Ubamatamab |
| Sponsor | Arcagy-Gineco |
| Geography | France |
| Enrollment | [object Object] |
| Primary endpoint | Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring period |
| Endpoint time frame | Up to 4 weeks of treatment |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab? Participants will: * Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles. * Attend regular clinic visits throughout the treatment period for checkups and tests
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across France shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring period (Up to 4 weeks of treatment) — Incidence of Treatment emergent adverse events according to NCI CTCAE version 6.0 (Safety and Tolerability)
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring period (Up to 4 weeks of treatment) — Dose-limiting toxicities (DLT) occurring during the DLT period (Safety and Tolerability)
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring period (From Cycle 1 Day 1 of the first patient included to Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days) (Safety and Tolerability)) — The recommended dose for phase II trial (RP2D) of ubamatamab in combination with carboplatin-paclitaxel + bevacizumab
- Efficacy phase II part (1 month after Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days).) — Objective response rate (ORR): Percentage of patients experiencing complete (CR) or partial response (PR) as the best overall radiological response after 3 cycles of ubamatamab in combination with carboplatin-paclitaxel-bevacizumab based on RECIST 1.1 criteria
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Ubamatamab is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Arcagy-Gineco is resolved to a normalized organization record in France. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07637851 provides a focused lens on Ovarian Cancer development. Its value will be determined by whether Ubamatamab can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
